Galecto GB1211 reduces signs of liver impairment in GULLIVER-2 trial; data presented at AASLD

Damora Therapeutics, Inc.

GB1211 well-tolerated with predictable PK; showed reductions in liver enzymes and FibroScan, indicating decreased inflammation and steatosis.
Part 2 data selected as 'Best of The Liver Meeting' in NASH/NAFLD category.
Preclinical rabbit model: GB1211 significantly reduced inflammation, fibrosis, and fat vs control.
Galecto to host webinar Nov 8, 2022 at 8:00 AM ET to discuss expanded topline data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.